Articles

PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy

BJH - 2018, issue Abstract Book BHS, february 2018

S. Dubruille PhD, C. Kenis , Y. Libert PhD, M. Delforge MD, PhD, L. Dal Lago , M. Roos , C. Borghgraef , dr. A. Salaroli MD, M. Maerevoet MD, D. Razavi MD, PhD, H. Wildiers , D. Bron MD, PhD

Read more

PP39 An unusual case of paraneoplastic nephrotic syndrome in a patient with chronic lymphocytic leukemia

BJH - 2018, issue Abstract Book BHS, february 2018

C. Spilleboudt , F. Paciorkowski , M. Vercruyssen MD, L. Bienfait , M. Depierreux , M. Maerevoet MD, D. Bron MD, PhD, J. Nortier

Read more

PP40 Anti-Pd1 inhibitor follow by Allo Stem cell transplantation in 3 heavily pretreated lymphoma’s patients: Experience from Institut Jules Bordet

BJH - 2018, issue Abstract Book BHS, february 2018

M. Maerevoet MD, P. Lewalle MD, PhD, N. Meuleman MD, PhD, C. Spilleboudt , dr. A. Salaroli MD, S. Wittnebel MD, PhD

Read more

New therapeutic approaches in cutaneous T-cell lymphomas

BJH - volume 8, issue 3, june 2017

D. Bron MD, PhD, C. Springael MD, PhD, M. Maerevoet MD, M. de Vicq MD, A. Kolivras MD

SUMMARY

Cutaneous T-cell lymphoma is a heterogeneous group of T-cell neoplasms presenting in the skin, mycosis fungoides being the most common subtype and Sézary syndrome the leukemic form. Treatment is dependant on stage and responses to previous therapy. Treatments are divided into ‘skin-directed therapies’, which are first-line for early stage diseases, and ‘systemic therapies’ reserved for advanced stages or refractory cutaneous T-cell lymphoma. There are currently no curative therapies for cutaneous T-cell lymphoma and consecutive treatments have to be given in function of the progression of the disease. There is an urgent need for new therapies to treat symptoms, particularly pruritus and pain, and to prolong survival. This paper summarises new drugs available for cutaneous T-cell lymphoma and their mode of action. Most new drugs for cutaneous T-cell lymphoma have response rates between 30% and 50% with response durations being less than a year. New studies looking at combination or maintenance therapies may improve quality of life and disease outcome.

(BELG J HEMATOL 2017;8(3):102–6)

Read more

P18 Early discontinuation of lenalidomide in patients with relapsing or refractory multiple myeloma: predictive factors for stopping in the real life

BJH - volume 8, issue Abstract Book BHS, february 2017

A. Pistone , M. Maerevoet MD, S. Wittnebel MD, PhD, M. Vercruyssen MD, S. Buntinx , C. Spilleboudt , D. Bron MD, PhD, N. Meuleman MD, PhD

Read more

P20 Results of laparoscopic splenectomy for benign and malignant hemopathies

BJH - volume 8, issue Abstract Book BHS, february 2017

D. Bron MD, PhD, dr. A. Salaroli MD, N. Meuleman MD, PhD, M. Maerevoet MD, M. Vercruyssen MD, C. Spilleboudt , A. De Wind MD, G. Dapri , G.B. Cadiere , B. Cadiere

Read more

O.1 A new frailty scoring in ‘clinically fit’ older patients with malignant hemopathies admitted to receive chemotherapy

BJH - volume 8, issue Abstract Book BHS, february 2017

S. Dubruille PhD, C. Kenis , Y. Libert PhD, M. Delforge MD, PhD, J. Alexis Ruiz , M. Roos , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, D. Razavi MD, PhD, H. Wildiers , D. Bron MD, PhD

Read more
X